Evidence map›Paper›PMID 40784025›Full record

ArticleOncoimmunology2025

A preclinical model for the identification of therapeutically active transgenes in local cancer immunotherapy.

Arne Menze, Dmitrij Ostroumov, Hans Heinrich Wedemeyer, Valery Volk, Friedrich Feuerhake, Florian Kühnel, Thomas Christian Wirth

Abstract read
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arne MenzeDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Dmitrij OstroumovDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Hans Heinrich WedemeyerDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Valery VolkInstitute of Pathology, Hannover Medical School, Hannover, Germany.ORCID 0000-0001-8335-5330
Friedrich FeuerhakeInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Florian KühnelDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Thomas Christian WirthDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of systemic immunotherapies is limited for poorly immunogenic tumors which suppress T cell priming and tumor infiltration. Modern antigen carriers including viral vectors and messenger RNA/lipid nanoparticle (LNP) combinations have renewed the interest in local immunotherapy due to their ability to express multiple transgene constructs simultaneously. The identification of therapeutically active combinations, however, is hampered by the lack of preclinical models to rapidly express and evaluate transgenes combinations

Indexed as

Colonic NeoplasmsImmunotherapyTransgenesAnimalsCell Line, TumorChemokine CXCL9Disease Models, AnimalFemaleGenetic TherapyHumansInterleukin-12Membrane ProteinsMiceMice, Inbred C57BLNanoparticlesT-LymphocytesChemokine CXCL9flt3 ligand proteinInterleukin-12Membrane ProteinsCD8 T cellslocoregional immunotherapysolid tumorstransgene expressiontumor microenvironment

Identifiers

PMID40784025
PMCPMC12952746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.